公司資料
Sera Prognostics 股價、新聞與催化劑
- 股票代碼:
- SERA
- 交易所:
- NASDAQ
- 產業:
- MedTech
- 所在地:
- United States
股票表現
1.95 USD (-0.51%)
收盤價
最後更新: 2026年8月17日
79.9M USD
市值
股價為何變動
As of Aug 17, 2026, SERA closed down 0.51% at $1.95. No new same-company headline was identified in the current news window.
公司概覽
Precision Pregnancy Diagnostics
Sera Prognostics develops blood-based biomarker tests intended to identify pregnancy risks before complications become clinically apparent. Its objective is to support earlier, personalized intervention for mothers and newborns.
PreTRM Test
The PreTRM Test measures maternal blood proteins during weeks 18 through 20 of pregnancy to estimate an individual's risk of spontaneous preterm birth. Physicians can use the result to guide risk-reduction care for higher-risk pregnancies.
Clinical Evidence Base
The test is supported by validation studies and the PRIME randomized controlled trial, which evaluates the clinical and economic effects of PreTRM-guided care. Sera continues to publish subgroup and health-economic analyses from this evidence base.
Payer-Led Adoption Model
Sera works with health plans and state-based programs to implement testing across covered populations. This model combines payer contracting, provider education, reimbursement readiness, and integration into prenatal-care pathways.
Pregnancy Complications Pipeline
Beyond spontaneous preterm birth, Sera is developing diagnostic approaches for other pregnancy complications using its proteomic biomarker platform.
未來催化劑
- Completion of the European CE-mark submission for the PreTRM Test in the fourth quarter of 2026.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。